
    
      Study design: Phase I/II study The Phase I study is open-label with four increasing dose
      levels for up to four 21-day cycles. Safety and activity will be evaluated at the end of each
      cycle.

      The Phase II study is open label with administration of the recommended phase dose of PTX-200
      for up to four 21-day cycles. PTX-200 will be co-administered with cytarabine in both the
      Phase I and Phase II parts of the study.
    
  